Journal article
10 Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial
- Abstract:
-
Background: New treatments are required for patients with resistance to current renal cell cancer (RCC) therapies. In contrast to the success of immunotherapy and VEGF directed therapies, few treatments have successfully targeted the RCC cell directly. Pre-clinical data suggests that PARP inhibitors have activity against RCC, and PARP inhibitors have been investigated in advanced RCC either alone or combined with VEGF directed therapy. Neoadjuvant window of opportunity studies allow us to und...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 924.8KB, Terms of use)
-
- Publisher copy:
- 10.1093/oncolo/oyaf276.011
Authors
- Publisher:
- Oxford University Press
- Journal:
- The Oncologist More from this journal
- Volume:
- 30
- Issue:
- Supplement_2
- Article number:
- oyaf276.011
- Publication date:
- 2025-10-09
- DOI:
- EISSN:
-
1549-490X
- ISSN:
-
1083-7159
- Language:
-
English
- Keywords:
- Pubs id:
-
2301598
- Local pid:
-
pubs:2301598
- Source identifiers:
-
3358189
- Deposit date:
-
2025-10-09
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
If you are the owner of this record, you can report an update to it here: Report update to this record